Linked Life Data

18790245

Source:http://linkedlifedata.com/resource/pubmed/id/18790245

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7
pubmed:dateCreated
2008-9-15
pubmed:abstractText
Sirolimus (SRL), an immunosuppressant shown to possess anti-proliferative properties, was hypothesized to mitigate the occurrence of posttransplantation malignancy. We examined its effect on posttransplantation urothelial carcinoma (UC).
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0041-1345
pubmed:author
pubmed:issnType
Print
pubmed:volume
40
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2395-6
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
Sirolimus does not absolutely abolish the occurrence/recurrence of urothelial carcinoma in renal transplant recipients.
pubmed:affiliation
Department of Urology, National Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan.
pubmed:publicationType
Journal Article, Case Reports